×
Don't Miss Out!
Get your weekly Breakfast Briefing eNewsletter, filled with news, trends, and vital information from DIA!
Back to Agenda
Global Evolution in Regulatory Science and Medicine: Novel Modalities and Intersection with Rare Disease Development
Session Chair(s)
Nina S. Cauchon, PhD, RAC
Director Regulatory Affairs CMC
Amgen, United States
We explore the rapid advancements in science and medicine leading to new complexities in the drug development ecosystem for rare diseases. Also, we examine and deliberate on the heterogeneous nature of regulatory frameworks globally for the treatment
Learning Objective : Discuss the intersection of precision medicine and rare disease drug development, including potential challenges; Explain, in general terms, about the global regulatory policy issues facing rare disease drug development.
Have an account?